US 9,518,976 B2 · Methods for identifying or assaying for agents that increase beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decrease fat mass

Abstract

The present invention is directed to cell-based and non-cell based methods of drug screening to identify agents, or assay agents, that reduce OST-PTP or gamma-carboxylase activity or expression, or increase the level of undercarboxylated osteocalcin or adiponectin activity or expression. Such agents find use in treating or preventing a disorder related to the OST-PTP signaling pathway. Such disorders include, metabolic syndrome, glucose intolerance, type 1 or type 2 diabetes, atherosclerosis, or obesity. Such agents may be used to treat disorders characterized by decreased insulin production, deceased insulin sensitivity, and decreased glucose tolerance or increased fat mass.

Claims4

Dependent claims

A method for identifying an agent that reduces osteocalcin carboxylation comprising:

(a) determining a first level of carboxylated osteocalcin in a first cell that expresses osteocalcin,
(b) contacting a second cell that expresses osteocalcin with the agent and determining a second level of carboxylated osteocalcin in the second cell, and
(c) comparing the first level of carboxylated osteocalcin with the second level of carboxylated osteocalcin,
wherein the first cell and the second cell have been genetically engineered to overexpress osteocalcin, and wherein the agent is identified as an agent that reduces osteocalcin carboxylation if the first level of carboxylated osteocalcin is higher than the second level.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

12/441,060Filed 13 Sep 2007 · us provisional application

Priority

13 Sep 2006

Published

US 2010/0048409 A125 Feb 2010

Granted

13 Dec 2016

Term ends

Not estimatedThe source records don’t support an estimate.

Classification28 codes

G01N 33/54306
With an insoluble carrier for immobilising immunochemicals: solid-phase reaction mechanisms
A61K 38/16
Medicinal preparations containing peptides: peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A61K 38/39
From animals; from humans: connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
A61K 47/60
Obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes: the organic…

Family

Application60/844,203Us provisional application · filed 13 Sep 2006

Application60/870,604Us provisional application · filed 18 Dec 2006

Application60/909,712Us provisional application · filed 2 Apr 2007

Application60/945,081Us provisional application · filed 19 Jun 2007

US 2010/0048409 A1Pre-grant publication · published 25 Feb 2010

US 9,518,976 B2This patent

From the US filing history. Foreign family members aren’t listed.

Methods for identifying or assaying for agents that increase beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decrease fat mass

Life of this patent

Methods for identifying or assaying for agents that increase beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decrease fat mass

Life of this patent

Abstract

Claims4